Acropolis Investment Management increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 33,900 shares of the company’s stock after buying an additional 225 shares during the period. Johnson & Johnson comprises about 0.7% of Acropolis Investment Management’s investment portfolio, making the stock its 19th largest position. Acropolis Investment Management’s holdings in Johnson & Johnson were worth $3,482,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. Eagle Asset Management raised its stake in Johnson & Johnson by 3,851.2% in the third quarter. Eagle Asset Management now owns 1,871,956 shares of the company’s stock worth $174,746,000 after buying an additional 1,824,579 shares during the last quarter. Fisher Asset Management raised its stake in Johnson & Johnson by 1.2% in the fourth quarter. Fisher Asset Management now owns 10,815,964 shares of the company’s stock worth $1,111,016,000 after buying an additional 126,481 shares during the last quarter. Churchill Management acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $9,159,000. Mondrian Investment Partners raised its stake in Johnson & Johnson by 11.5% in the fourth quarter. Mondrian Investment Partners now owns 668,836 shares of the company’s stock worth $68,703,000 after buying an additional 69,095 shares during the last quarter. Finally, Assetmark raised its stake in Johnson & Johnson by 288.0% in the third quarter. Assetmark now owns 87,528 shares of the company’s stock worth $8,171,000 after buying an additional 64,970 shares during the last quarter.

Shares of Johnson & Johnson (NYSE:JNJ) opened at 101.18 on Wednesday. The firm’s 50-day moving average price is $100.69 and its 200 day moving average price is $98.61. Johnson & Johnson has a 12-month low of $81.79 and a 12-month high of $105.49. The company has a market cap of $279.96 billion and a price-to-earnings ratio of 19.42.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 26th. The company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.42 by $0.02. During the same quarter in the prior year, the company posted $1.27 EPS. The business had revenue of $17.80 billion for the quarter, compared to analysts’ expectations of $17.88 billion. The business’s revenue for the quarter was down 2.4% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post $6.18 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 8th. Stockholders of record on Tuesday, February 23rd will be issued a dividend of $0.75 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.61. The ex-dividend date of this dividend is Friday, February 19th. This represents a $3.00 annualized dividend and a dividend yield of 2.97%.

JNJ has been the subject of a number of research analyst reports. BTIG Research reissued a “buy” rating and issued a $115.00 target price on shares of Johnson & Johnson in a report on Sunday, November 1st. Piper Jaffray initiated coverage on Johnson & Johnson in a report on Monday, October 5th. They issued a “neutral” rating and a $105.00 target price for the company. Credit Suisse reissued a “neutral” rating on shares of Johnson & Johnson in a report on Monday. Morgan Stanley reissued an “equal weight” rating on shares of Johnson & Johnson in a report on Tuesday, October 13th. Finally, Raymond James reissued an “outperform” rating and issued a $105.00 target price (down previously from $108.00) on shares of Johnson & Johnson in a report on Friday, January 22nd. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $107.58.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

12 Month Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.